巨子 ICON - 財經股票資訊及專家分析
搜尋 股票

Bellicum Pharmaceuticals

BLCM
最少15分鐘延遲,股票資訊由第三方資訊供應商提供
・Bellicum Pharmaceuticals - 延遲價格・最後更新於 19/01 8:25
最高位
1.460
最低位
1.420
開市價
--
前收市價
1.400
成交量(千)
0.48
成交額(百萬)
0.01
買入
--
賣出
3.820
每手股數
--
市值(百萬)
12.18
市盈率
0.540
息率
--
差價
--
52週高低
8.150 - 1.400
所有資料不保證絕對正確、完整、或實時,僅作為參考使用。投資涉及風險,過往業績並不代表將來表現,作任何投資決定或交易前,閣下應諮詢獨立專業意見。所有內容均不構成投資建議。

企業資料

公司名稱
Bellicum Pharmaceuticals
證券代碼
BLCM.US
所屬板塊
Biotechnology
公司業務
Bellicum Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. Its research areas are cellular immunotherapies for hematological cancers, solid tumors, and orphan inherited blood diseases. The company's expertise is based on the inclusion of powerful molecular switches planned to eliminate, reduce, or activate therapeutic cells to increase efficacy and safety compared with existing cell therapies. Its pipeline portfolio includes adjunct T-cell therapy (Rivo-cel) to treat leukemias, lymphomas, and genetic blood diseases; CAR T cells technology (BPX-601) to treat prostate, pancreatic, bladder, esophagus, and gastric cancers; and BCMA GoCAR-NK the program targeting B-cell maturation antigen.
發行量
8318273
公司總部
3730 Kirby Drive, Suite 1200
公司網址
http://www.bellicum.com
公司電話
+1 832 384-1100
暫無內容

關於

Bellicum Pharmaceuticals(BLCM.US)所屬的行業板塊為Biotechnology。
Bellicum Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. Its research areas are cellular immunotherapies for hematological cancers, solid tumors, and orphan inherited blood diseases. The company's expertise is based on the inclusion of powerful molecular switches planned to eliminate, reduce, or activate therapeutic cells to increase efficacy and safety compared with existing cell therapies. Its pipeline portfolio includes adjunct T-cell therapy (Rivo-cel) to treat leukemias, lymphomas, and genetic blood diseases; CAR T cells technology (BPX-601) to treat prostate, pancreatic, bladder, esophagus, and gastric cancers; and BCMA GoCAR-NK the program targeting B-cell maturation antigen.
詳細公司背景可參考: http://www.bellicum.com